Project Details
Description
An open label, multicenter roll-over extension program (REP) to characterize the long- term safety and tolerability of iptacopan (LNP023) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have completed PNH Phase II and Phase III studies wit
| Status | Active |
|---|---|
| Effective start/end date | 12/6/23 → 12/31/33 |
Funding
- NOVARTIS PHARMACEUTICALS CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.